

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Cannvas MedTech Inc. (the “Company” or “Cannvas”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Item 2: Date of Material Change

June 27, 2019.

Item 3: News Release

A news release was disseminated on June 26, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced corporate updates on strategic initiatives and issued shares.

Item 5: Full Description of Material Change

The Company announced significant growth in the digital traffic to its cannabis education platform Cannvas.Me, an unbiased evidence-based cannabis education resource providing physician-backed and educator-approved cannabis learning on all aspects of the plant with no pressure to purchase or consume. Cannvas is also pleased to share recent company updates across a series of initiatives and strategic partnerships.

In April, Cannvas announced a definitive partnership with Seed Technology, a California-based interactive customer-focused cannabis education platform, granting Cannvas exclusive Canadian rights to distribute co-branded kiosks and related technology to medical clinics and retailers across Canada. Cannvas Kiosks have been well-received by existing partners, including Empower Clinics (CSE: CBDT) (FRA: 8EC) (OTC: EPWCCF), a network of physician-staffed medical clinics in Arizona, Illinois, Nevada, Oregon and Washington State actively treating more than 165,000 patients, with whom Cannvas signed a definitive partnership to be its exclusive cannabis education provider and data and analytics partner through the installation of on-site Cannvas Kiosks. Cannvas and Seed continue to work closely together on various initiatives in the Canadian and U.S. markets actively moving towards international markets expansion in the near future.

In May, Cannvas officially launched its digital cannabis education resource for animals, Cannvas.Pet. Powered by the Cannvas.Me and Cannvas Data platforms, Cannvas.Pet explores health care through cannabis-based products to help treat a pet or animal’s ailments. With a focus on American audiences, Cannvas.Pet expects to be a leader in an industry in which, according to BDS Analytics, sales of cannabis-related products for pets at dispensaries in California, Colorado, Oregon and Washington was nearly \$7 million in 2017. In Colorado alone, sales of pet products grew 49 per cent that year, while all other product categories only reached 15 per cent growth. Interest in the platform has been significant north of the border as well, especially in light of Health Canada’s recent announcement regarding “Cannabis Health Products”, a new category of cannabis that could potentially open up a huge market in which marijuana is used for the therapeutic treatment of animals for minor ailments.

In the coming weeks, Cannvas anticipates the appointment of several prominent Canadians and Americans to newly-formed Advisory Boards helping guide the content and direction of its digital education properties. To date in 2019, Cannvas has added several high-profile names to its Advisory Boards:

- Brad Poulos recently joined the Educational Advisory Board to provide independent oversight and guidance for Cannvas.Me. Mr. Poulos is currently on faculty and teaching the Business of Cannabis at the Ted Rogers School of Management at Toronto’s Ryerson University, and an in-demand public speaker on the topics of business and the cannabis industry.
- Dinesh Kandanchatha is leading the AI, Technology and Data Advisory Board, and brings with him a wealth of knowledge and expertise in the technology sector as founder and former Chief Technology Officer of Patriot One Technologies (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL), a concealed weapons detection system that promises a safer world.
- Wesley Tulshi also joined the AI, Technology and Data Advisory Board. Mr. Tulshi is currently based in Silicon Valley and serves as Director, Hololens HW Group at Microsoft, helping develop wearable mixed reality technology powered by artificial intelligence.

- Angela Smith, PhD is leading the Cannabis Sciences Advisory Board, providing independent scientific oversight for Cannabis.Me and bringing with her a wealth of experience in medical, scientific and clinical affairs for Canadian medicinal and recreational cannabis brands and natural health products, and leading international food brands.
- Emma Chasen, a leading U.S.-based cannabis educator and industry consultant, joined the Cannabis Sciences Advisory Board to provide educational content focused on the science of cannabis, leveraging her academic training in plant chemistry and experience working with leading cannabis brands in developing educational programs for staff and customers.

Its digital cannabis education platform Cannabis.Me continues to experience consistently strong growth, underscoring the need for unbiased cannabis education for cannabis consumers around the world. Month-over-month user growth on Cannabis.Me was up 34% in May and 61% in June, to date. Average time on site increased to 12 minutes and 40 seconds and month-over-month page views increased 369% in June to date. This suggests the audience for cannabis education is growing at a rapid rate and could be correlated to the continued relaxation of cannabis laws in countries around the world.

Cannvas Data has continued its approach of collecting and analyzing pre-cursor data, and remains among the only companies looking at what drives cannabis consumption through behavioural patterns and trends. As the Cannabis.Me site grows, the data collected becomes more valuable as a resource for businesses in and outside the cannabis industry to better understand what drives consumers to purchase cannabis.

Cannvas continues its focus on strategic merger and acquisition opportunities since engaging Catapult Growth Partners, a leading North American-based consultancy firm focused on helping businesses accelerate profitable growth and increase equity value, to explore transactions within the global cannabis sector and maximize shareholder value.

Its Cannabis Cannabis Acquisitions arm, a wholly-owned subsidiary with a focus on investment and acquisition in the expanding global cannabis sector, continues to position existing cannabis consumer trends and syncing datasets to monetize through strategic partnerships and M&A opportunities. Significant focus and aggressive global expansion is planned outside of Canada, with specific updates to be provided in the near future.

The previous financing announced by Cannabis has been cancelled at the company's direction, while the company, alongside Cannabis Cannabis Acquisitions Corp, focuses on various strategic M&A opportunities which, if successful, would provide optimal shareholder value. Further details will be provided in due course as due diligence progresses.

Additionally, the company has issued an aggregate of 2,983,850 common shares of the Company at a deemed value of 21 cents per share to a related party of the company, pursuant to the services rendered.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

CannvasMedTech.com

Contact: ir@cannvasmedtech.com

Item 9: Date of Report

June 27, 2019.